Tigrelia Tablet 60 mg (Ticagrelor)

Adult dosage

This medicine should not be used in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took this medicine at 90mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this medicine at 60mg. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration instructions. Data on the safety and efficacy of this medicine for treatment lasting more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink the mixture. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Children's dosage

Safety and efficacy have not been established in pediatric patients under 18 years of age (refer to “Other”).

This medication prevents platelet aggregation in the blood, thus preventing clot formation. Therefore, it should not be used in patients with current bleeding or a history of bleeding disorders due to an increased risk of bleeding. If surgical procedures are planned, this medication should be discontinued at least 5 days prior. It is not indicated for patients with severe liver dysfunction or allergies to the medication. In addition, patients with compromised liver or kidney function, the elderly, and those on specific medications should use this drug cautiously. Extra care is needed when taking other medications that increase the risk of bleeding alongside this drug. Patients with asthma or chronic obstructive pulmonary disease should be cautious when taking this drug, as breathing difficulties may occur. Pregnant or nursing women should consult with a physician before taking this drug, and women of childbearing age should avoid pregnancy during the treatment period. Safety and efficacy have not been established for patients under 18 years of age. Overdose may increase the risk of bleeding, and there are no specific antidotes to manage it. If symptoms such as dizziness or confusion occur during treatment, caution should be exercised when driving or operating machinery. Since this drug is metabolized in the liver, care is needed in patients with reduced liver function or in combination with specific liver metabolic inhibitors. This drug may also interact with various other medications, so patients must inform their healthcare provider of any other medications they are taking.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• dyspnea
• respiratory tract hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is important to maintain the storage temperature between 1 and 30 degrees Celsius. Therefore, it should be kept in a cool, dry place until use, and exposure to direct sunlight or high temperatures should be avoided.

Appearance

Pink, double-convex, round film-coated tablet

Package unit

60 tablets (10 tablets/PTP x 6)